DBVT News and Press, DBV Technologies S.A. From 07/13/20

DBV Technologies Reports Positive Extension Study Results DBV Technologies (DBVT) reported positive results from its open label extension of the Phase 3 study. The data showed that the participants underwent sustained clinical benefit with an extra two years of treatment with Viaskin Pea...

DBV Technologies ( DBVT ) announces results from a three-year open-label extension, PEOPLE , of the Phase 3 PEPITES study evaluating Viaskin Peanut in children with peanut allergy. The data were just published in The Journal of Allergy and Clinical Immunology.  More news on: D...

Montrouge, France, July 7, 2020 DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology PEOPLE is the largest long-term peanut allergy immunotherapy trial to date and showed fav...

DBV Technologies (NASDAQ: DBVT) , a biopharmaceutical company based in France, provided a business update today regarding Viaskin, a potential peanut allergy treatment the company developed that is currently being reviewed by the U.S. Food and Drug Administration (FDA). DBV Technologies expre...

Milestone Scientific (NYSEMKT: MLSS )  -20%  after pricing equity offering. More news on: Milestone Scientific Inc., DBV Technologies S.A., Ideanomics, Inc., Stocks on the move, , Read more ...

Montrouge, France, June 26, 2020 DBV Technologies Provides Operational and Business Update BLA review of Viaskin Peanut for the treatment of peanut allergy in children ages 4-11 years ongoing Company to immediately initiate restructuring plan to extend cash runway while awaitin...

Aimmune Therapeutics (NASDAQ: AIMT) has performed significantly worse than the broader market of late. The company's stock fell by more than 50% during the first quarter of the year, and even though it has rebounded somewhat, Aimmune's shares are still down by 43% year to date. If Aimmune ca...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...

Montrouge, France, June 4, 2020 DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 Virtual presentations will include data about children with and without multiple food allergies from the pivotal Phase III peanu...

Montrouge, France, June 2, 2020 DBV Technologies To Present at the Goldman Sachs 41 st Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced th...